menu
    • menu
    [{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Pimecrolimus","moa":"FK506-binding protein 1A","graph1":"Dermatology","graph2":"Phase III","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Glenmark Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Glenmark Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Famy Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"INDIA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Pimecrolimus","moa":"FK506-binding protein 1A","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Famy Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Famy Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Famy Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"University of Kiel","sponsor":"Deutsche Forschungsgemeinschaft, Bonn, Germany | Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Pimecrolimus","moa":"FK506-binding protein 1A","graph1":"Dermatology","graph2":"Undisclosed","graph3":"University of Kiel","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"University of Kiel \/ Deutsche Forschungsgemeinschaft, Bonn, Germany | Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"1","companyTruncated":"University of Kiel \/ Deutsche Forschungsgemeinschaft, Bonn, Germany | Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Actavis Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Pimecrolimus","moa":"FK506-binding protein 1A","graph1":"Dermatology","graph2":"Phase III","graph3":"Actavis Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Actavis Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Actavis Inc \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Pimecrolimus","moa":"FK506-binding protein 1A","graph1":"Dermatology","graph2":"Phase I","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Pimecrolimus","moa":"FK506-binding protein 1A","graph1":"Dermatology","graph2":"Phase I","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Viatris","sponsor":"DPT Laboratories, Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Pimecrolimus","moa":"FK506-binding protein 1A","graph1":"Dermatology","graph2":"Phase III","graph3":"Viatris","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Viatris \/ DPT Laboratories, Ltd","highestDevelopmentStatusID":"10","companyTruncated":"Viatris \/ DPT Laboratories, Ltd"},{"orgOrder":0,"company":"Par Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Pimecrolimus","moa":"FK506-binding protein 1A","graph1":"Dermatology","graph2":"Phase III","graph3":"Par Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Par Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Par Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Emer, Jason, M.D.","sponsor":"Ferndale Laboratories, Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Pimecrolimus","moa":"FK506-binding protein 1A","graph1":"Dermatology","graph2":"Phase IV","graph3":"Emer, Jason, M.D.","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Emer, Jason, M.D. \/ Ferndale Laboratories, Inc.","highestDevelopmentStatusID":"11","companyTruncated":"Emer, Jason, M.D. \/ Ferndale Laboratories, Inc."}]

    Find Clinical Drug Pipeline Developments & Deals for Pimecrolimus

    Menu

    Pimecrolimus

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Famy Life Sciences

                            India arrow
                            Tides Europe
                            Not Confirmed

                            Famy Life Sciences

                            India arrow
                            Tides Europe
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pimecrolimus

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Phase 3 Study to Evaluate the Efficacy and Safety of Pimecrolimus 0.3% Ophthalmic Ointment

                            Details : Pimecrolimus is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Blepharitis.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 06, 2024

                            Lead Product(s) : Pimecrolimus

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Par Pharmaceutical

                            U.S.A arrow
                            Tides Europe
                            Not Confirmed

                            Par Pharmaceutical

                            U.S.A arrow
                            Tides Europe
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pimecrolimus

                            Therapeutic Area : Dermatology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety and Bioequivalence of Pimecrolimus Cream 1% and Elidel R in Treatment of Mild to Moderate Atopic Dermat...

                            Details : Pimecrolimus is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Dermatitis, Atopic.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 29, 2017

                            Lead Product(s) : Pimecrolimus

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Viatris

                            U.S.A arrow
                            Tides Europe
                            Not Confirmed

                            Viatris

                            U.S.A arrow
                            Tides Europe
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pimecrolimus

                            Therapeutic Area : Dermatology

                            Study Phase : Phase III

                            Sponsor : DPT Laboratories, Ltd

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Bioequivalence Study of Pimecrolimus Cream, 1% and Elidel® Cream, 1% in Mild to Moderate Atopic Dermatitis

                            Details : Pimecrolimus is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Dermatitis, Atopic.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 11, 2017

                            Lead Product(s) : Pimecrolimus

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase III

                            Sponsor : DPT Laboratories, Ltd

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Glenmark Pharmaceuticals

                            India arrow
                            Tides Europe
                            Not Confirmed

                            Glenmark Pharmaceuticals

                            India arrow
                            Tides Europe
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pimecrolimus

                            Therapeutic Area : Dermatology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study of Generic Pimecrolimus Cream, 1% in the Treatment of Mild to Moderate Atopic Dermatitis

                            Details : Pimecrolimus is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Dermatitis, Atopic.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 12, 2016

                            Lead Product(s) : Pimecrolimus

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Actavis Inc

                            Ireland arrow
                            Tides Europe
                            Not Confirmed

                            Actavis Inc

                            Ireland arrow
                            Tides Europe
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pimecrolimus

                            Therapeutic Area : Dermatology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study of Equivalence of Generic Pimecrolimus Cream 1% and Elidel® 1% in Subjects With Mild to Moderate Atop...

                            Details : Pimecrolimus is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Dermatitis, Atopic.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 06, 2016

                            Lead Product(s) : Pimecrolimus

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Leo Pharma

                            Denmark arrow
                            Tides Europe
                            Not Confirmed

                            Leo Pharma

                            Denmark arrow
                            Tides Europe
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pimecrolimus

                            Therapeutic Area : Dermatology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Clinical Trial to Compare Topical Agents in Adults With Mild to Moderate Atopic Dermatitis (AD)

                            Details : Pimecrolimus is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Dermatitis, Atopic.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 03, 2015

                            Lead Product(s) : Pimecrolimus

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Leo Pharma

                            Denmark arrow
                            Tides Europe
                            Not Confirmed

                            Leo Pharma

                            Denmark arrow
                            Tides Europe
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pimecrolimus

                            Therapeutic Area : Dermatology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Multi-Centre Clinical Trial to Evaluate a Left-Right Design in Adults With Mild to Moderate Atopic Dermatiti...

                            Details : Pimecrolimus is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Dermatitis, Atopic.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 04, 2014

                            Lead Product(s) : Pimecrolimus

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Emer, Jason, M.D.

                            Country arrow
                            Tides Europe
                            Not Confirmed

                            Emer, Jason, M.D.

                            Country arrow
                            Tides Europe
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pimecrolimus

                            Therapeutic Area : Dermatology

                            Study Phase : Phase IV

                            Sponsor : Ferndale Laboratories, Inc.

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Pimecrolimus Cream 1% (Elidel®) and Medicated Device Cream (EletoneTM) in the Treatment and Maintenance of ...

                            Details : Pimecrolimus is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Dermatitis, Atopic.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 09, 2010

                            Lead Product(s) : Pimecrolimus

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase IV

                            Sponsor : Ferndale Laboratories, Inc.

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            University of Kiel

                            Country arrow
                            Tides Europe
                            Not Confirmed

                            University of Kiel

                            Country arrow
                            Tides Europe
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pimecrolimus

                            Therapeutic Area : Dermatology

                            Study Phase : Undisclosed

                            Sponsor : Deutsche Forschungsgemeinschaft, Bonn, Germany | Novartis Pharmaceuticals Corporation

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Pimecrolimus and Epidermal Barrier Function

                            Details : Pimecrolimus is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Dermatitis, Atopic.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 27, 2010

                            Lead Product(s) : Pimecrolimus

                            Therapeutic Area : Dermatology

                            Highest Development Status : Undisclosed

                            Sponsor : Deutsche Forschungsgemeinschaft, Bonn, Germany | Novartis Pharmaceuticals Corporation

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth